Anecortave Acetate for the Treatment of Exudative Age-Related Macular Degeneration-A Review of Clinical Outcomes

Survey of Ophthalmology

Volumn 52, Issue 1 SUPPL., 2007, Pages

  Russell, Stephen R ^a   Hudson, Henry L ^b   Jerdan, Janice A ^c  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b Retina Centers PC   (United States)

^c ALCON RESEARCH LTD   (United States)

Author keywords

anecortave acetate; choroidal neovascularization; exudative age related macular degeneration; photodynamic therapy; posterior juxtascleral depot administration

Indexed keywords

ANECORTAVE; BENZOPORPHYRIN DERIVATIVE; PLACEBO;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PHOTODYNAMIC THERAPY; POSTERIOR JUXTASCLERAL DEPOT ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZATION; RETINA EXUDATE; RETINA MACULA AGE RELATED DEGENERATION; STATISTICAL SIGNIFICANCE; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; TREATMENT OUTCOME; TRIGEMINAL NERVE DISEASE;

ANGIOGENESIS INHIBITORS; CHOROIDAL NEOVASCULARIZATION; CLINICAL TRIALS; EXUDATES AND TRANSUDATES; HUMANS; MACULAR DEGENERATION; PREGNADIENEDIOLS; TREATMENT OUTCOME;

EID: 33846198991     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.survophthal.2006.11.005     Document Type: Article

References (25)

1. -. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin in Photodynamic. Am J Ophthalmol 131 (2001) 541-560
2. -. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP). Arch Ophthalmol 117 (1999) 1329-1345
3. -. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol 109 (1991) 1109-1114
4. -. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol 109 (1991) 1220-1231
5. -. Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol 108 (1990) 816-824
6. Augustin A.J., D'Amico D.J., Mieler W.F., et al. Safety of posterior juxtascleral depot administration of the angiostatic cortisene anecortave acetate for treatment of subfoveal choroidal neovascularization in patients with age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 243 (2005) 9-12
7. Blinder K.J., Bradley S., Bressler N.M., et al. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol 136 (2003) 407-418
8. Bocci G., Francia G., Man S., et al. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci USA 100 (2003) 12917-12922
9. Bressler N.M. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 119 (2001) 198-207
10. Bressler N.M. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 119 (2001) 198-207
11. Bressler S.B., Bressler N.M., Fine S.L., et al. Natural course of choroidal neovascular membranes within the foveal avascular zone in senile macular degeneration. Am J Ophthalmol 93 (1982) 157-163
12. Clark A.F., et al. Preclinical efficacy of anecortave acetate. Surv Ophthalmol 52 Suppl 1 (2007) S41-S48
13. Clark A.F. AL-3789: a novel ophthalmic angiostatic steroid. Expert Opin Investig Drugs 6 (1997) 1867-1877
14. D'Amico D.J., Goldberg M.F., Hudson H., et al. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration (AMD): 12-month clinical outcomes. Ophthalmology 110 (2003) 2372-2383 discussion 2384-5
15. D'Amico D.J., Goldberg M.F., Hudson H., et al. Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD): interim (month 6) analysis of clinical safety and efficacy. Retina 23 (2003) 14-23
16. Green W.R., and Enger C. Age-related macular degeneration histopathologic studies. The 1992 Lorenz E. Zimmerman Lecture. Ophthalmology 100 (1993) 1519-1535
17. Grisanti S., Tatar O., Canbek S., et al. Immunohistopathologic evaluation of choroidal neovascular membranes following verteporfin-photodynamic therapy. Am J Ophthalmol 137 (2004) 914-923
18. Kaiser P.K., Goldberg M.F., and Davis A.A. Posterior juxtascleral depot administration of anecortave acetate. Surv Ophthalmol 52 Suppl 1 (2007) S62-S69
19. Michels S., and Schmidt-Erfurth U. Sequence of early vascular events after photodynamic therapy. Invest Ophthalmol Vis Sci 44 (2003) 2147-2154
20. Regillo C.D., D'Amico D.J., Mieler W.F., et al. Clinical safety profile of posterior juxtascleral depot administration of anecortave acetate 15 mg suspension as primary therapy or adjunctive therapy with PDT. Surv Ophthalmol 52 Suppl 1 (2007) S70-S78
21. Schmidt-Erfurth U.M., and Michels S. Changes in confocal indocyanine green angiography through two years after photodynamic therapy with verteporfin. Ophthalmology 110 (2003) 1306-1314
22. Slakter J.S., Bochow T.W., D'Amico D.J., et al. Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration. Ophthalmology 113 (2006) 3-13
23. Slakter J.S., Carvalho C., and Coleman H. The digital angiography reading center (DARC) role in the anecortave acetate clinical trials. Surv Ophthalmol 52 Suppl 1 (2007) S91-S98
24. Slaton J.W., Karashima T., Perrotte P., et al. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder. Clin Cancer Res 7 (2001) 2840-2853
25. Weis M., Heeschen C., Glassford A.J., and Cooke J.P. Statins have biphasic effects on angiogenesis. Circulation 105 (2002) 739-745